ERBB2 and breast cancer: A recent study has reported that CUL7 may increase trastuzumab resistance in Her2-positive BC cells by degrading Ser phosphorylation of IRS-1 and activating the PI3K/AKT pathway, which is of great significance for selecting the optimal treatment plan for BC patients.